Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

PRISM Registry: Pseudobulbar Affect Registry Series

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Avanir Pharmaceuticals
ClinicalTrials.gov Identifier:
NCT01366027
First received: June 2, 2011
Last updated: April 15, 2014
Last verified: April 2014

June 2, 2011
April 15, 2014
May 2011
September 2012   (final data collection date for primary outcome measure)
Prevalence of PBA (using CNS-LS) [ Time Frame: Upon Study Enrollment/Entry ] [ Designated as safety issue: No ]
The objective of the registry is to determine the prevalence of pseudobulbar affect (PBA) in patients with certain underlying neurologic conditions: Alzheimer's Disease (AD), Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), Parkinson's Disease (PD), Stroke (STR), and Traumatic Brain Injury (TBI). Presence of PBA symptoms was defined as CNS-LS score >=13.
Not Provided
Complete list of historical versions of study NCT01366027 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
PRISM Registry: Pseudobulbar Affect Registry Series
PRISM Registry: Pseudobulbar Affect Registry Series

PBA is a neurologic condition that is estimated to impact over a million patients and their families in the United States. PBA occurs secondary to an otherwise unrelated neurologic disease or injury, and manifests as involuntary, frequent, and disruptive outbursts of crying and/or laughing. Progress has been made in better understanding this debilitating condition, but much more needs to be done. That's why a new PBA patient registry, PRISM (Pseudobulbar Affect RegIstry Series), has been initiated.

The goal of PRISM is to establish the prevalence and quality of life (QOL) impact of PBA in patients with underlying neurologic conditions including

  • Alzheimer's disease
  • Amyotrophic lateral sclerosis
  • Multiple sclerosis
  • Parkinson's disease
  • Stroke
  • Traumatic brain injury

Because this is an observational registry, it doesn't require you to intervene with any specific treatment or procedure. Your participation allows the PRISM registry to collect and analyze data from your site and also compare it to national numbers captured in the PRISM registry about PBA across all of the major at-risk neurologic populations.

Not Provided
Observational
Not Provided
Not Provided
Not Provided
Probability Sample

The population for this study will be 18 years and over

  • Alzheimer's Disease
  • Amyotrophic Lateral Sclerosis (ALS)
  • Multiple Sclerosis (MS)
  • Parkinson's Disease
  • Stroke
  • Traumatic Brain Injury
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
5290
September 2012
September 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • All participants must have underlying neurologic conditions known to be risk factors of PBA: Alzheimer's Disease, Amyotrophic Lateral Sclerosis, Multiple Sclerosis, Parkinson's Disease, Stroke, and Traumatic Brain Injury.
  • The population for this study will be 18 years and over
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01366027
11-AVR-REG-001
No
Avanir Pharmaceuticals
Avanir Pharmaceuticals
Not Provided
Study Chair: Randall Kaye, MD Avanir Pharmaceuticals
Avanir Pharmaceuticals
April 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP